
    
      This expanded access program enables the pediatric participants with a high unmet medical
      need to continue receiving lanadelumab during the interim period between completion of the
      SHP643-301 (NCT04070326 [SPRING study]) and Food and Drug Administration (FDA) review and
      potential approval in the age group (2 to <12 years) has been granted and when the product is
      commercially approved for this age group .
    
  